Currently, there are 379.09M common shares owned by the public and among those 365.93M shares have been available to trade.
The company’s stock has a 5-day price change of 17.14% and 1.65% over the past three months. LAB shares are trading -40.00% year to date (YTD), with the 12-month market performance down to -29.71% lower. It has a 12-month low price of $0.92 and touched a high of $2.41 over the same period. LAB has an average intraday trading volume of 1.29 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 16.06%, 12.03%, and -18.96% respectively.
Institutional ownership of Standard BioTools Inc (NASDAQ: LAB) shares accounts for 72.28% of the company’s 379.09M shares outstanding.
It has a market capitalization of $467.18M and a beta (3y monthly) value of 1.50. The earnings-per-share (ttm) stands at -$0.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.55% over the week and 6.05% over the month.
Earnings per share for the fiscal year are expected to increase by 55.47%, and 37.16% over the next financial year. EPS should grow at an annualized rate of 66.44% over the next five years, compared to 11.61% over the past 5-year period.
TD Cowen coverage for the Standard BioTools Inc (LAB) stock in a research note released on April 16, 2024 offered a Buy rating with a price target of $3.50. Jefferies was of a view on April 04, 2024 that the stock is Buy, while KeyBanc Capital Markets gave the stock Overweight rating on July 12, 2023, issuing a price target of $4.
